Luc M. Van Nueten
Beerse, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers.
Journal: Journal of psychopharmacology (Oxford, England)
Published: May 11, 2023
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.
Journal: Translational psychiatry
Published: June 06, 2022
Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture: A guide to sample type and time.
Journal: Comprehensive psychoneuroendocrinology
Published: January 07, 2022
Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Journal: Journal of Alzheimer's disease : JAD
Published: March 15, 2021
The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: June 29, 2020
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans.
Journal: Translational psychiatry
Published: April 30, 2020
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
Journal: Journal of psychopharmacology (Oxford, England)
Published: April 07, 2020
Association of cognitive activities of daily living (ADL) function and nonmotor burden in nondemented Parkinson's disease patients.
Journal: Neuropsychology
Published: March 20, 2020
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
Journal: Alzheimer's research & therapy
Published: February 04, 2020
Neuroendocrine and Inflammatory Effects of Childhood Trauma Following Psychosocial and Inflammatory Stress in Women with Remitted Major Depressive Disorder.
Journal: Brain sciences
Published: November 11, 2019
Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Journal: Translational psychiatry
Published: October 04, 2019
Last Updated: 09/26/2026